RMC-4550

• CAT Number: I019737
• CAS Number: 2172651-73-7
• Molecular Formula: C₂₁H₂₆Cl₂N₄O₂
• Molecular Weight: 437.36
• Purity: ≥95%
• Target: Metabolic Enzyme/Protease
• IUPAC Name: [3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol
• InChI: InChI=1S/C21H26Cl2N4O2/c1-12-18(14-4-3-5-15(22)17(14)23)26-16(10-28)20(25-12)27-8-6-21(7-9-27)11-29-13(2)19(21)24/h3-5,13,19,28H,6-11,24H2,1-2H3/t13-,19+/m0/s1
• InChIKey: IKUYEYLZXGGCRD-ORAYPTAESA-N
• SMILES: C[C@H]1[C@H](C2(CCN(CC2)C3=NC(=C(N=C3CO)C4=C(C(=CC=C4)Cl)Cl)C)CO1)N

RMC-4550（Cat No.:I019737）is an experimental small molecule inhibitor developed by Revolution Medicines, targeting the SHP2 (Src homology region 2 domain-containing phosphatase-2) enzyme. SHP2 plays a key role in various signaling pathways, including those involved in cancer cell growth, survival, and metastasis. By inhibiting SHP2, RMC-4550 aims to block these pathways, thereby reducing tumor proliferation and enhancing the efficacy of other cancer treatments, such as immune checkpoint inhibitors. RMC-4550 is being investigated in clinical trials for solid tumors, particularly those with mutations in the RAS/RAF/MEK/ERK pathway, to assess its safety and effectiveness.

Reference

[1]. Nichols RJ, et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol. 2018 Sep;20(9):1064-1073.